Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children

doi:10.1177/0269881116658986

機構典藏 > College of Sciences > Graduate Institute & Department of Mathematics > Journal Article > Item 987654321/109559

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/109559

Title:	Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children
Authors:	Tzang, Ruu-Fen;Chang, Yue-Cune;Tsai, Guo-Chuan E.;Lane, Hsien-Yuan
Date:	2016-10-21
Issue Date:	2017-02-24 02:10:43 (UTC+8)
Publisher:	Sage Publications Ltd.
Abstract:	Methylphenidate, a stimulant that activates dopaminergic and noradrenergic function, is an important agent in the treatment of attention deficit hyperactivity disorder (ADHD). Sarcosine, a glycine transporter-1 inhibitor, may also play a role in treating ADHD by modulating the glutamatergic neurotransmission system through activating N-methyl-D-aspartate type glutamate receptors. This study aimed to assess the efficacy of sarcosine in treating children with ADHD. We conducted a six-week, randomized, double-blind, placebo-controlled clinical trial. The primary outcome measures were those on the Inattention, Hyperactivity/impulsivity, and oppositional defiant disorder (ODD) subscales of the Swanson, Nolan, and Pelham, version IV scale. Efficacy and safety were measured bi-weekly. A total of 116 children with ADHD were enrolled. Among them, 48 (83%) of the 58 sarcosine recipients and 44 (76%) of the 58 placebo recipients returned for the first post-treatment visit. The missing data values were imputed by the last observation carry forward method. From a multiple linear regression analysis, using the generalized estimating equation approach, and an intention to treat analysis, the efficacy of sarcosine marginally surpassed that of placebo at weeks 2, 4, and 6, with p-values=0.01, 0.026, and 0.012, respectively, although only for ODD symptoms. Treatment of ADHD by sarcosine (0.03 g/kg/day) was well tolerated. Sarcosine could possibly be a novel agent for managing ODD symptoms in the context of ADHD. However, future larger-scale studies are warranted to optimize its dosage.
Relation:	Journal of Psychopharmacology 30(10), p.976-982
DOI:	10.1177/0269881116658986
Appears in Collections:	[Graduate Institute & Department of Mathematics] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	273	View/Open
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children.pdf		238Kb	Adobe PDF	2	View/Open

Loading...